Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
University of Nottingham · Inserm · +9 more institutions
Abstract
BACKGROUND: The increasing use of higher-than-approved doses of clopidogrel in clinical practice is based in part on the desire for greater levels of inhibition of platelet aggregation (IPA). Prasugrel is a new thienopyridine that is more potent than standard-dose clopidogrel in healthy subjects and patients with stable coronary artery disease. The relative antiplatelet effects of prasugrel versus high-dose clopidogrel in percutaneous coronary intervention patients are unknown. METHODS AND RESULTS: Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 (PRINCIPLE-TIMI 44) was a randomized, double-blind, 2-phase crossover study of…
Citation impact
- FWCI
- 59.17
- Percentile
- 100%
- References
- 41
Authors
16- SDStephen D. WiviottCorresponding
University of Nottingham, Inserm, University of Massachusetts Chan Medical School, Eli Lilly (United States), Sheba Medical Center, University of Florida, Massachusetts General Hospital, Universitäts-Herzzentrum Freiburg-Bad Krozingen, Nottingham Scientific (United Kingdom), Nottingham Biomedical Research Centre, Florida College
- DTDietmar Trenk
University of Nottingham, Inserm, University of Massachusetts Chan Medical School, Eli Lilly (United States), Sheba Medical Center, University of Florida, Massachusetts General Hospital, Universitäts-Herzzentrum Freiburg-Bad Krozingen, Nottingham Scientific (United Kingdom), Nottingham Biomedical Research Centre, Florida College
- ALAndrew L. Frelinger
University of Nottingham, Inserm, University of Massachusetts Chan Medical School, Eli Lilly (United States), Sheba Medical Center, University of Florida, Massachusetts General Hospital, Universitäts-Herzzentrum Freiburg-Bad Krozingen, Nottingham Scientific (United Kingdom), Nottingham Biomedical Research Centre, Florida College
- MLMichelle L. O’Donoghue
University of Nottingham, Inserm, University of Massachusetts Chan Medical School, Eli Lilly (United States), Sheba Medical Center, University of Florida, Massachusetts General Hospital, Universitäts-Herzzentrum Freiburg-Bad Krozingen, Nottingham Scientific (United Kingdom), Nottingham Biomedical Research Centre, Florida College
- FNFranz‐Josef Neumann
University of Nottingham, Inserm, University of Massachusetts Chan Medical School, Eli Lilly (United States), Sheba Medical Center, University of Florida, Massachusetts General Hospital, Universitäts-Herzzentrum Freiburg-Bad Krozingen, Nottingham Scientific (United Kingdom), Nottingham Biomedical Research Centre, Florida College
Topics & keywords
- Medicine
- Prasugrel
- Clopidogrel
- Percutaneous coronary intervention
- Maintenance dose
- Loading dose
- Cardiology
- Internal medicine
- Good health and well-being